Current Research Studies

Pediatric And Young Adult Leukemia Adoptive Therapy (PLAT)-08: A Phase 1 Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

PLAT-08

Condition(s): Acute Myeloid Leukemia (AML), Leukemia & Lymphoma, Recurrent and/or Refractory
Phase: I
Clinicaltrials.gov ID: NCT05105152

What is the goal of the study?

This phase 1, open-label, non-randomized study will enroll pediatric and young adult patients with relapsed or refractory CD33+ leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility of administering an autologous T cell product that has been genetically modified to express a Dimerizing Agent Regulated Immunoreceptor Complex (DARIC).

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Adam Lamble
Study Team Member: HemOnc CRAs, HemOncCRAs@seattlechildrens.org